Abstract
e14628 Background: The aim of this retrospective study (from January 2007 to December 2011) was to investigate the efficacy and tolerability of mDCF schedule for chemotherapy naïve AGC patients. Methods: Patients (n=54) with locally inoperable or distant metastasis, and performance status of 0–2 were eligible. The triplet combination chemotherapy consists of docetaxel 60 mg/m2 day 1, cisplatin 60 mg/m2 day 1, 5-flourouracil 600 mg/m2 for 5 days continuous infusion were administered every 21 days, up to 9 cycles. Prophylactic G-CSF was not allowed. Two of the patients treated with second line cisplatin/capecitabine. None of the patients treated with radiotherapy. Results: In all, 36 (67%) patients were male and 18 (33%) were female; median age was 59 years (range: 23-80 years). Majority of patients (n=46, 85%) were metastatic disease and 8 (15%) of them were locally advanced disease. Liver metastasis and peritonitis carcinomatosa were found in 20 (%43) and 18 (39%) of the 46 cases, respectively. The median cycle of chemotherapy was 6 (ranging from 1 to 9 cycles). In assessing fifty patients for response evaluation, one had complete response. The partial responses achieved in 27 (54%) patients. Seventeen patients (34%) had stable disease and 5 (10%) progressed. Of 2% (n=4) and 11% (n=6) of the patients developed severe (grade 3-4) neutropenia and anemia, respectively. One patient developed febrile neutropenia. Severe thrombocytopenia, hepatic and renal toxicity were not seen. During median follow-up time (8.1 months, range: 1.3-24), 28 (52%) patients were died. The overall and progression-free survival were 11.6 [95% CI: 10.2-13] and 7.7 [95% CI: 6.8-8.7] months, respectively. Conclusions: Although this was not a prospective comparative study, the mDCF regimen seems to be as effective as original DCF in AGC with acceptable and manageable side effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.